Vitamin B-12 Therapy

Number: 0536

Policy

1. Medically Necessary Indications

   Aetna considers intramuscular or subcutaneous vitamin B-12 injections medically necessary only for members with current or previously documented B-12 deficiency and any of the following diagnoses and conditions:

   1. Anemia

      • Fish tapeworm anemia; or
      • Macrocytic anemia; or
      • Megaloblastic anemia; or
      • Pernicious anemia (Addisonian anemia, Biermer’s anemia).

   2. Gastrointestinal disorders

      • Conditions associated with decreased production of intrinsic factor; or
      • Malabsorption syndromes (e.g.,sprue, idiopathic steatorrhea, and other malabsorption syndromes); or
      • Surgical or mechanical disorders (e.g., gastrectomy (subtotal or total), blind loop syndrome, intestinal anastomosis, intestinal strictures, and resection of the small intestine).

   3. Neuropathy

      • Acute phase or acute exacerbation of a neuropathy due to malnutrition or alcoholismFootnotes for neuropathy^*; or
      • Neuropathies associated with pernicious anemia (Addisonian anemia, Biermer’s anemia); or
      • Posterolateral sclerosis.

   4. Dementia Secondary

      Dementia secondary to vitamin B-12 deficiency

   5. Homocystinuria

      Homocystinuria

   6. Methotrexate or Pralatrexate

      Members receiving methotrexate or pralatrexate (Folotyn)Footnotes for pralatrexate^* (see CPB 0740 - Pralatrexate (Folotyn))

   7. Pemetrexed (Alimta)

      Members receiving pemetrexed (Alimta)Footnotes for pemetrexed^* (see CPB 0687 - Pemetrexed (Alimta))

   8. Metformin

      Members with vitamin B-12 deficiency due to use of metformin that is not corrected by oral vitamin B-12

   9. Methylmalonic aciduria

      Methylmalonic aciduria

   10. Tobacco Amblyopia

       Retrobulbar neuritis associated with heavy smoking, also known as tobacco amblyopia.

   Physician administration of intramuscular or subcutaneous vitamin B-12 injections is considered medically necessary for the diagnoses and conditions listed above.

   Intramuscular or subcutaneous administration of vitamin B-12 injections for more than 2 to 3 months is subject to review to ascertain if deficiency/abnormalities have improved and to decide whether continued treatment is medically necessary. 

   Footnotes^* Documentation of B-12 deficiency is not required in these circumstances.

2. Experimental indications

   Aetna considers vitamin B-12 injections experimental and investigational for all other indications, including use for the treatment of age-related cataract, amyotrophic lateral sclerosis, autism, chronic fatigue syndrome (myalgic encephalomyelitis), delayed sleep-wake phase disorder, non-24-hour sleep-wake rhythm disorder, depression, diabetic peripheral neuropathy, elevated homocysteine in persons not diagnosed with homocysteinuria, fibromyalgia, impaired cognitive function (except for dementia secondary to vitamin B-12 deficiency), peripheral entrapment neuropathies (e.g., carpal tunnel syndrome), post-herpetic neuralgia, and tinnitus; for the prevention of osteoporotic fracture, for the reduction of cardiovascular risks, for the prevention of stroke, and as adjunctive therapy for weight loss because there is insufficient evidence in the peer-reviewed literature to support the use of B-12 injections for these indications.

   Note: Most Aetna plans exclude coverage of nutritional supplements.  Under these plans, Aetna does not cover charges for oral vitamins that can be purchased without a prescription, or for oral vitamins that are prescribed solely as a dietary supplement even if a physician’s prescription is needed for purchase.  Please check benefit plan descriptions.

3. Homocysteine

   Aetna considers measurement of serum homocysteine medically necessary in persons with borderline vitamin B-12 deficiency, where the results will impact the member's management (See CPB 0763 - Homocysteine Testing). 
   
   

   See also

   • CPB 0348 - Recurrent Pregnancy Loss;
   • CPB 0381 - Cardiac Disease Risk Tests; and 
   • CPB 0562 - Biochemical Markers of Bone Remodeling.

4. Holotranscobalamin

   Aetna considers measurements of holotranscobalamin (a biologically active vitamin B-12 fraction) for the diagnosis of vitamin B-12 deficiency experimental and investigational because its clinical value has not been established.

Background

Vitamin B-12 belongs to the family of cobalamins.  It is available in all animal-derived foods, and is absorbed at a rate of 5 mcg per day.  After being ingested, vitamin B-12 becomes bound to intrinsic factor, a protein secreted by gastric parietal cells.  The vitamin B-12/intrinsic factor complex is absorbed in the terminal ileum by cells with specific receptors for the complex.  The absorbed complex is then transported via plasma and stored in the liver.  Since the liver stores 2,000 to 5,000 mcg vitamin B-12 (adequate for up to 5 years), dietary deficiency of cobalamin (Cbl) is rare.  In most cases, vitamin B-12 deficiency is due to an inability of the intestine to absorb the vitamin, which may result from an autoimmune disease that reduces the production or blocks the action of intrinsic factor, or from other diseases that result in intestinal malabsorption.  The most frequent underlying cause of vitamin B-12 deficiency is pernicious anemia, which is associated with decreased production of intrinsic factor.  Abdominal surgery may cause Cbl deficiency in several ways: gastrectomy eliminates the site of intrinsic factor production; blind loop syndrome results in competition for vitamin B-12 by bacterial overgrowth in the lumen of the small intestine; and surgical resection of the ileum eliminates the site of vitamin B-12 absorption.  Rare causes of vitamin Cbl deficiency include pancreatic insufficiency; fish tapeworm infection, in which the parasite uses luminal vitamin B-12; and severe Crohn’s disease, resulting in reduced ileal absorption of vitamin B-12.

Cobalamin deficiency is more common in the elderly primarily because of the increasing prevalence with age of Cbl malabsorption due to autoimmune atrophic gastritis.

Most patients with overt Cbl deficiency report serum vitamin B-12 levels of less than 100 pg/ml.  The hallmark of vitamin B-12 deficiency is megaloblastic anemia.  Vitamin B-12 deficiency also leads to neurological deficits including paresthesias, sensory loss, ataxia, disequilibrium, diminished or hyperactive reflexes, and spasticity.  In more advanced cases, cerebral function may also be affected resulting in disturbances of mood, psychoses, and dementia.

In a systematic review of randomized trials on vitamin B-6, B-12, and folic acid supplementation and cognitive function, Balk and colleagues (2007) stated that despite their important role in cognitive function, the value of B vitamin supplementation is unknown.  A total of 14  trials met selection criteria; most were of low quality and limited applicability.  Approximately 50 different cognitive function tests were assessed.  Three trials of vitamin B-6 and 6 of vitamin B-12 found no effect overall in a variety of doses, routes of administration, and populations.  One of 3 trials of folic acid found a benefit in cognitive function in people with cognitive impairment and low baseline serum folate levels.  Six trials of combinations of the B vitamins all concluded that the interventions had no effect on cognitive function.  Among 3 trials, those in the placebo arm had greater improvements in a small number of cognitive tests than participants receiving either folic acid or combination B-vitamin supplements.  The evidence was limited by a sparsity of studies, small sample size, heterogeneity in outcomes, and a lack of studies that evaluated symptoms or clinical outcomes.  The authors concluded that there is insufficient evidence of an effect of vitamin B-6, B-12, or folic acid supplementation, alone or in combination, on cognitive function testing in people with either normal or impaired cognitive function.  This is in agreement with Clarke et al (2007) who stated that randomized trials are needed to ascertain the relevance of vitamin B-12 supplementation for the prevention of dementia.

In a randomized, double-blind, placebo-controlled trial, Albert et al (2008) examined if a combination of folic acid, vitamin B-6, and vitamin B-12 lowers risk of cardiovascular disease (CVD) among high-risk women with and without CVD.  A total of 5,442 women aged 42 years or older, with either a history of CVD or 3 or more coronary risk factors, were enrolled in this study.  Subjects received a combination pill containing 2.5 mg folic acid, 50 mg vitamin B-6, and 1 mg vitamin B-12 or a matching placebo, and were treated for 7.3 years.  Main outcome measures were a composite outcome of myocardial infarction, stroke, coronary re-vascularization, or CVD mortality.  Compared with placebo, a total of 796 women experienced a confirmed CVD event (406 in the active group and 390 in the placebo group).  Patients receiving active vitamin treatment had similar risk for the composite CVD primary end point (226.9/10,000 person-years versus 219.2/10,000 person-years for the active versus placebo group; relative risk [RR], 1.03; 95 % confidence interval [CI]: 0.90 to 1.19; p = 0.65), as well as for the secondary outcomes including myocardial infarction (34.5/10,000 person-years versus 39.5/10,000 person-years; RR, 0.87; 95 % CI: 0.63 to 1.22; p = 0.42), stroke (41.9/10,000 person-years versus 36.8/10,000 person-years; RR, 1.14; 95 % CI: 0.82 to 1.57; p = 0.44), and CVD mortality (50.3/10,000 person-years versus 49.6/10,000 person-years; RR, 1.01; 95 % CI: 0.76 to 1.35; p = 0.93).  In a blood substudy, geometric mean plasma homocysteine level was decreased by 18.5 % (95 % CI: 12.5% to 24.1%; p < 0.001) in the active group (n = 150) over that observed in the placebo group (n = 150), for a difference of 2.27 micromol/L (95 % CI: 1.54  to 2.96 micromol/L).  The authors concluded that after 7.3 years of treatment and follow-up, a combination pill of folic acid, vitamin B-6, and vitamin B-12 did not reduce a combined end point of total cardiovascular events among high-risk women, despite significant homocysteine lowering.

Vitamin B-12 therapy can be administered orally or by injection.  Vitamin B12 tablets of up to 5,000 mcg may be obtained over the counter without a prescription. 

In a review on vitamin B-12 deficiency, Oh and Brown (2003) noted that, because most clinicians are generally unaware that oral vitamin B-12 therapy is effective, the traditional treatment for B-12 deficiency has been intramuscular injections.  The authors cited evidence that demonstrates, however, that oral vitamin B-12 has been shown to have an efficacy equal to that of injections in the treatment of pernicious anemia and other B-12 deficiency states (Elia, 1998; Lederle, 1998; Kuzminski et al, 1998; Lederle, 1991).   The authors explained that, although the majority of dietary vitamin B-12 is absorbed in the terminal ileum through a complex with intrinsic factor, there is mounting evidence that approximately 1 % of a large dose of oral vitamin B-12 is absorbed by simple diffusion which is independent of intrinsic factor or even an intact terminal ileum.

Kuzminzki et al (1998) reported on the outcome of 33 patients with vitamin B-12 deficiency who were randomized to receive oral or parenteral vitamin B-12 therapy.  Patients in the parenteral therapy group received 1,000 mcg of vitamin B-12 intramuscularly on days 1, 3, 7, 10, 14, 21, 30, 60, and 90, while those in the oral treatment group received 2,000 mcg daily for 120 days.  At the end of 120 days, patients who received oral therapy had significantly higher serum vitamin B-12 levels and lower methylmalonic acid levels than those in the parenteral therapy group.

Adachi et al (2000) reported the results of a study that showed that even in patients who had undergone gastrectomy, vitamin B-12 deficiency could be easily reversed with oral supplementation.

Oh and Brown (2003) explained that intramuscular injections have several drawbacks. Injections are painful, medical personnel giving the injections are placed at risk of needlestick injuries, and administration of intramuscular injections often adds to the cost of therapy.

Lane and Rojas-Fernandez (2002) reported on a meta-analysis of studies of oral versus parenteral therapy for vitamin B-12 deficiency.  The investigators concluded that daily oral vitamin B-12 at doses of 1,000 to 2,000 mcg can be used for treatment in most cobalamin-deficient patients who can tolerate oral supplementation. The investigators noted, however, that there are inadequate data at the present time to support the use of oral vitamin B-12 replacement in patients with severe neurologic involvement.  The investigators explained that oral cyanocobalamin replacement may not be adequate for a patient presenting with severe neurologic manifestations that could have devastating consequences if the most rapid-acting therapy is not used immediately. Therefore, parenteral cobalamin is preferable in neurologically symptomatic patients until resolution of symptoms and hematologic indices.

Although the daily requirement of vitamin B-12 is approximately 2 mcg, the initial oral replacement dosage consists of a single daily dose of 1,000 to 2,000 mcg (Lederle, 1991; Oh and Brown, 2003).  This high dose is required because of the variable absorption of oral vitamin B-12 in doses of 500 mcg or less.  This regimen has been shown to be safe, cost-effective, and well tolerated by patients.

Treatment schedules for intramuscular administration vary widely but usually consist of initial loading doses followed by monthly maintenance injections.  Little (1999) recommended an initial treatment of intramuscular injections of vitamin B-12 1,000 mcg daily for 5 days, followed by 1,000 mg weekly for 4 weeks, and a maintenance therapy of 1,000 mcg every 1 to 3 months.  Intramuscular injections of Cbl are well-tolerated. 

Hematological improvements should commence within 5 to 7 days, and the deficiency should resolve after 3 to 4 weeks of therapy.  However, 6 months or longer of Cbl treatment may be needed before appearance of signs of improvement in neurological manifestations of vitamin B-12 deficiency.  Total or partial resolution of neurological deficits has been reported in as many as 80 % of patients (Healton et al, 1991).  Neurological improvement is less likely to occur in patients with severe or longstanding deficiency, and in patients with less severe accompanying anemia.

Guidelines from the British Columbia Medical Association (2003) state that "[o]ral doses of vitamin B12 are as effective as parenteral administration in treating deficiency in most cases."  The guidelines include the following recommendation: “Oral replacement of vitamin B12 is the treatment of choice in most cases, including pernicious anemia.  Patients with significant neurological deficits, however, should receive initial intramuscular injections of 1,000 micrograms vitamin B12, followed by oral doses of 1,000-2,000 micrograms/day.  The duration of therapy depends on the cause of deficiency.  In pernicious anemia treatment is life-long.  Early treatment of vitamin B12 deficiency is particularly important because neurologic symptoms may be irreversible.”

Guidelines for Serum cobalamin (pmol/L) and Probability of symptomatic deficiency

Serum cobalamin (pmol/L)	Probability of symptomatic deficiency
Less than 75	High
75 to 150	Moderate
150 to 220	Low
Greater than 220	Rare

The British Columbia Guidelines and Protocols Advisory Committee (2012) states that oral crystalline cyanocobalamin (commonly available form) is the treatment of choice. Dosing for pernicious anemia or food-bound cobalamin malabsorption is 1000 mcg/day. In most other cases a dose of 250 mcg/day may be used. The guidelines state that oral administration of cobalamin is as effective as parenteral.Advantages of oral supplementation mentioned in the guidelines are comfort, ease of administration, and cost. The guidelines state that prophylactic cobalamin supplementation is recommended for strict vegans and patients with food bound cobalamin malabsorption, and for pernicious anemia. The usefulness of prophylactic administration of cobalamin in elderly is unknown. The guidelines state that parenteral administration should be reserved for those with significant neurological symptoms. It includes 1-5 intramuscular or subcutaneous injections of 1000 mcg crystalline cyanocobalamin daily, followed by oral doses of 1000-2000 mcg/day. The guidelines recommend retesting serum cobalamin levels after 4-6 months to ensure they are in the normal range.

In general, the medically necessary initial parenteral dose for medically necessary diagnoses (other than pemetrexed administration, see below) consists of 1,000 mcg vitamin B-12 daily for 5 days, then 1,000 mg weekly for 4 weeks.  For maintenance therapy, 1,000 mcg every 1 to 3 months is usually medically necessary.  Requests for vitamin B-12 injections more frequently than the schedule stated above is subject to medical review.

Pemetrexed disodium (Alimta) was approved by the Food and Drug Administration (FDA) on February 5, 2004.  It is the first drug approved for mesothelioma.  The recommended dose of Alimta is 500 mg/m2 administered as an intravenous infusion over 10 mins on day 1 of each 21-day cycle.  Patients must take daily doses of folic acid and vitamin B-12 to reduce the severity of side effects such as low white blood cell count, nausea, vomiting, fatigue, rash, and diarrhea.  Patients must receive 1 intra-muscular injection of 1,000 µg vitamin B-12 during the week preceding the first dose of Alimta and every 3 cycles thereafter.

Sanchez-Moreno et al (2009) noted that several studies have reported benefits on lowering the risk of stroke and improving the post-stroke-associated functional declines in patients who ate foods rich in micronutrients, including B vitamins and antioxidant vitamins E and C.  Folic acid, vitamin B-6 and vitamin B-12 are all co-factors in homocysteine metabolism.  Growing interest has been paid to hyper-homocysteinemia as a risk factor for cardiovascular disease.  Hyper-homocysteinemia has been linked to inadequate intake of vitamins, particularly to B-group vitamins and therefore may be amenable to nutritional intervention.  Hence, poor dietary intake of folate, vitamin B-6 and vitamin B-12 are associated with increased risk of stroke.  Elevated consumption of fruits and vegetables appears to protect against stroke.  Antioxidant nutrients have important roles in cell function and have been implicated in processes associated with ageing, including vascular, inflammatory and neurological damage.  Plasma vitamin E and C concentrations may serve as a biological marker of lifestyle or other factors associated with reduced stroke risk and may be useful in identifying those at high risk of stroke.  After reviewing the observational and intervention studies, there is an incomplete understanding of mechanisms and some conflicting findings; therefore the available evidence is insufficient to recommend the routine use of B vitamins, vitamin E and vitamin C for the prevention of stroke.  A better understanding of mechanisms, along with well-designed controlled clinical trials will allow further progress in this area.

Scott (2010) stated that "[v]itamin B12 has been touted as an energy enhancer and metabolism booster.  These claims are based on the fact that correcting vitamin B12 deficiency should improve the associated symptoms of fatigue and weakness; however, in the absence of a nutritional deficit, vitamin B12 supplementation does not affect physical performance.  No form of vitamin B12 (intra-muscular, oral, or other routes) has been credibly tested as an aid to weight loss.  A search of MEDLINE using the search terms "cyanocobalamin or vitamin B12" and "weight loss ordiet" yielded no clinical studies using vitamin B12 supplements.  Although no adverse effects have been associated with excess vitamin B12 intake from food and supplements in healthy people, weight loss programs that promote vitamin B12, particularly in injectable form, suggest treatment that is not based on sound evidence".

In a pilot study, Bertoglio and colleagues (2010) examined if methyl B-12 treatment improves behavioral measures in children with autism and whether improvement is associated with increased plasma concentrations of glutathione (GSH) and an increased redox ratio of reduced glutathione to oxidized glutathione (GSH/GSSG), both of which have been previously identified to be low in children with autism.  This was a 12-week, double-blind, placebo-controlled, cross-over clinical trial of injectable methyl B-12.  Following this 12-week study, subjects were given the option of entering a 6-month open-label trial of methyl B-12.  Subjects were 3 to 8 years old with autism.  All subjects received 6 weeks of placebo and 6 weeks of methyl B-12 at a dose of 64.5 mcg/kg every 3 days administered subcutaneously into the buttocks.  Blood for GSH analysis and behavioral assessments were obtained at baseline, week 6, and week 12.  A total of 30 subjects completed the 12-week, double-blind study, and 22 subjects completed the 6-month extension study.  No statistically significant mean differences in behavior tests or in glutathione status were identified between active and placebo groups.  Nine subjects (30 %) reported clinically significant improvement on the Clinical Global Impression Scale and at least 2 additional behavioral measures.  More notably, these responders exhibited significantly increased plasma concentrations of GSH and GSH/GSSG.  The authors concluded that comparison of the overall means between groups suggests that methyl B-12 is ineffective in treating behavioral symptoms of autism.  However, detailed data analysis suggests that methyl B-12 may alleviate symptoms of autism in a subgroup of children, possibly by reducing oxidative stress.  An increase in glutathione redox status (GSH/GSSG) may provide a biomarker for treatment response to methyl B-12.  They statedthat additional research is needed to delineate a subgroup of potential responders and ascertain a biomarker for response to methyl B-12.

O'Leary et al (2012) noted that poor vitamin B-12 status may lead to the development of cognitive decline and dementia but there is a large variation in the quality, design of and results reported from these investigations.  These researchers performed a systematic review of the evidence for the association between vitamin B-12 status and cognitive decline in older adults.  A database search of the literature to 2011 was undertaken, using keywords related to vitamin B-12 and cognition.  All prospective cohort studies assessing the association of serum vitamin B-12 or biomarkers were included.  Quality assessment and extraction of the data were undertaken by 2 researchers.  The quality assessment tool assigns a positive, neutral or negative rating.  Of 3,772 published articles, 35 cohort studies (14,325 subjects) were identified and evaluated.  No association between serum vitamin B-12 concentrations and cognitive decline or dementia was found.  However, 4 studies that used newer biomarkers of vitamin B-12 status (methylmalonic acid and holoTC) showed associations between poor vitamin B-12 status and the increased risk of cognitive decline or dementia diagnosis.  In general, the studies were of reasonable quality (21 positive, 10 neutral and 4 negative quality) but of short duration and inadequate subject numbers to determine whether an effect exists.  The authors concluded that future studies should be of adequate duration (at least 6 years), recruit subjects from the 7th decade, choose markers of vitamin B-12 status with adequate specificity such as holoTC and/or methylmalonic acid and employ standardized neurocognitive assessment tools and not screening tests in order to ascertain any relationship between vitamin B-12 status and cognitive decline.

Doets et al (2013) stated that current recommendations on vitamin B-12 intake vary from 1.4 to 3.0 μg per day and are based on the amount needed for maintenance of hematologic status or on the amount needed to compensate obligatory losses.  In a systematic review, these investigators evaluated whether the relation between vitamin B-12 intake and cognitive function should be considered for under-pinning vitamin B-12 recommendations in the future.  The authors summarized dose-response evidence from randomized controlled trials (RCTs) and prospective cohort studies on the relation of vitamin B-12 intake and status with cognitive function in adults and elderly people.  Two RCTs and 6 cohort studies showed no association or inconsistent associations between vitamin B-12 intake and cognitive function.  Random-effects meta-analysis showed that serum/plasma vitamin B-12 (50 pmol/L) was not associated with risk of dementia (4 cohort studies), global cognition z scores (4 cohort studies), or memory z scores (4 cohort studies).  Although dose-response evidence on sensitive markers of vitamin B-12 status (methylmalonic acid and holotranscobalamin) was scarce, 4 of 5 cohort studies reported significant associations with risk of dementia, Alzheimer's disease, or global cognition.  The authors concluded that current evidence on the relation between vitamin B-12 intake or status and cognitive function is not sufficient for consideration in the development of vitamin B-12 recommendations.  They stated that further studies should consider the selection of sensitive markers of vitamin B-12 status.

Current biochemical markers of vitamin B-12 deficiency include methylmalonic acid (MMA), homocysteine (Hcy) and cobalamin.  Serum concentrations of MMA and Hcy are increased in B-12-deficient patients due to inhibition of methylmalonyl-CoA mutase and methionine synthase, respectively.  Some authorities have recommended measurement of Hcy and MMA in persons with borderline vitamin B-12 deficiency, although it is usually easier to treat such cases with oral vitamin B-12 (BCMA, 2003).

In an editorial that addressed whether clinicians should routinely measure Hcy levels and treat patients with mild hyperhomocysteinemia, Rosenberg and Mulrow (2006) stated that clinicians need not routinely measure Hcy levels nor routinely treat mild hyperhomocysteinemia with folic acid or vitamin B supplementation.

Although total serum cobalamin is used to diagnose B-12 deficiency, it may not reliably indicate vitamin B-12 status.  A normal serum cobalamin concentration does not reliably rule out a functional cobalamin deficiency.  Previous studies have reported problems of sensitivity and specificity with this test (Green, 1996; Stabler, 1998).  On the other hand, serum level of holotranscobalamin (holoTC), a metabolically active cobalamin bound to the transport protein transcobalamin, becomes reduced prior to the development of metabolic dysfunction.  To enhance the sensitivity and specificity in diagnosing vitamin B-12 deficiency, some investigators have advocated measuring holoTC.  This is performed by giving a small oral dose of vitamin B-12 and assessing the subsequent increase in the amount of holoTC in the serum.  However, there is currently no gold standard or true reference method to diagnose subtle vitamin B-12 deficiency, which makes evaluation of the clinical usefulness of holoTC and the estimation of sensitivity and specificity problematic. 

The causes of vitamin B-12 deficiency in the elderly are only partly understood.  van Asselt and colleagues (2003) examined the role of the cobalamin-binding proteins regarding B-12 deficiency in older people, and tested the hypothesis that low saturated transcobalamin concentration is an early marker of B-12 deficiency.  Saturated (holo) and unsaturated (apo) transcobalamin and haptocorrin concentrations were measured in healthy middle-aged volunteers, healthy older volunteers, cobalamin-deficient older volunteers and cobalamin-deficient older patients.  Holo and apo concentrations of transcobalamin and haptocorrin were similar in healthy middle-aged and older subjects.  HoloTC concentrations were significantly reduced in cobalamin-deficient subjects but did not differ between healthy volunteers and patients.  Furthermore, the relative amount of cobalamin on transcobalamin was similar in all four groups.  These researchers concluded that abnormalities of the cobalamin-binding proteins are not a cause of vitamin B12 deficiency in the elderly.  Plasma holoTC concentration did not differ between stages of vitamin B12 deficiency in the elderly.  As a result, plasma holoTC is not an early marker of vitamin B12 deficiency in the elderly and has no additional value in the diagnostic work-up of reduced plasma cobalamin concentrations in older people.

Nilsson et al (2004) examined if low holoTC concentrations are congruent with other biochemical signs of cobalamin deficiency in a group of psychogeriatric patients.  The findings in their study showed that holoTC is strongly related to serum cobalamin (0.68; p < 0.001 in both patients and controls).  Distribution of the different markers for cobalamin/folate status in the 33 patients with low levels of serum holoTC (below 40 pmol/L) showed that 17 patients had normal levels of the other markers for cobalamin status.  This may indicate poor specificity of low holoTC for cobalamin deficiency.  In 23 out of 176 patients with normal levels of holoTC, pathological levels of other markers for cobalamin deficiency was observed.  The use of holoTC did not provide significant additional information other than that given by serum cobalamin and thus can not be recommended in this clinical setting.

Loikas et al (2003) assessed a commercial holoTC radioimmunoassay, determined reference values, and evaluated holoTC concentrations in relation to other biochemical markers of vitamin B-12 deficiency.  The reference population consisted of 303 subjects 22 to 88 years of age, without disease or medication affecting cobalamin or Hcy metabolism.  In elderly individuals (65 years or older), normal B-12 status was further confirmed by total Hcy (less than 19 micro mol/L) and MMA (less than 0.28 umol/L) concentrations within established reference intervals.  HoloTC in B12 deficiency was studied in a population of 107 elderly individuals with normal renal function.  B-12 deficiency was graded as potential (total vitamin B12 of 150 pmol/L or less; or total Hcy of 19 umol/L or more), possible (total B-12 of 150 pmol/L or less; AND either total Hcy of 19 micro mol/L or more, or MMA of 0.45 umol/L or more), and probable (total Hcy of 19 umol/L or more, AND MMA of 0.45 umol/L or more).  These investigators concluded that the holoTC radioimmunoassay is precise and simple to perform.  Low holoTC is found in persons with biochemical signs of vitamin B-12 deficiency, but the sensitivity and specificity of low holoTC in diagnosis of vitamin B-12 deficiency need to be further evaluated.

In a prospective study, Serefhanoglu et al (2008) assessed circulating holoTC to estimate the diagnosis of vitamin B-12 deficiency in the first ischemic cerebrovascular attack.  These researchers also compared the efficacy of the measurement of plasma holoTC with the other standard biochemical and hematological markers used to reach the diagnosis of Cbl deficiency.  A total of 45 patients (age 71 years; range of 35 to 90; 16 men and 29 women) within the first ischemic cerebrovascular event were included in this study.  All the enrolled patients received 1-mg vitamin B-12 intramuscular injection once-daily for 10 days.  At the baseline and on the 10th day of treatment, plasma levels of holoTC and the proper biochemical and hematological markers in diagnosing Cbl deficiency were measured.  After admission, anemia and diminished serum vitamin B-12 levels were determined to be only 20 % (9/45) and 44 % (20/45), respectively; 78 % (35/45) of the patients had low serum holoTC (less than 37 pmol/L).  Serum Hcy was higher in patients (49 % of them) who had suffered a stroke.  Thrombocytopenia, hyper-segmentated neutrophils, and indirect hyper-bilirubinemia were observed in 20 % of the patients.  Leukopenia and macrocytosis were not evident in any of them.  In 18 of 27 patients (67 %) that had low holoTC levels after joining the study and who remained in the study until the end of Cbl treatment, serum holoTC levels returned to normal values.  Cobalamin deficiency should be considered in patients with CVD, even if anemia, elevated mean cell volume, depression of the serum Cbl, or other classic hematological and/or biochemical abnormalities are lacking.  The authors noted that measurement of serum holoTC looks promising as a 1st-line of tests for diagnosing early vitamin B-12 deficiency.

In summary, the usefulness of holoTC in diagnosing B-12 deficiency in various clinical settings has not been established.  Large-scale clinical studies are needed to determine the clinical value of holoTC.

Regland et al (2015) noted that patients with myalgic encephalomyelitis (ME, also called chronic fatigue syndrome) may respond most favorably to frequent vitamin B-12 injections, in vital combination with oral folic acid.  However, there is no established algorithm for individualized optimal dosages, and rate of improvement may differ considerably between responders.  These researchers evaluated clinical data from patients with ME, with or without fibromyalgia, who had been on B-12 injections at least once-weekly for 6months and up to several years.  A total of 38 patients were included in a cross-sectional survey.  Based on a validated observer's rating scale, they were divided into good (n = 15) and mild (n = 23) responders, and the 2 groups were compared from various clinical aspects.  Good responders had used significantly more frequent injections (p < 0.03) and higher doses of B-12 (p < 0.03) for a longer time (p < 0.0005), higher daily amounts of oral folic acid (p < 0.003) in good relation with the individual MTHFR genotype, more often thyroid hormones (p < 0.02), and no strong analgesics at all, while 70 % of mild responders (p < 0.0005) used analgesics such as opioids, duloxetine or pregabalin on a daily basis.  In addition to ME, the higher number of patients with fibromyalgia among mild responders was bordering on significance (p < 0.09).  Good responders rated themselves as "very much" or "much" improved, while mild responders rated "much" or "minimally" improved.  The authors concluded that dose-response relationship and long-lasting effects of B-12/folic acid support a true positive response in the studied group of patients with ME/fibromyalgia.  It's important to be alert on co-existing thyroid dysfunction, and the authors suspected a risk of counteracting interference between B-12/folic acid and certain opioid analgesics and other drugs that have to be demethylated as part of their metabolism.  These issues should be considered when controlled trials for ME and fibromyalgia are to be designed.  This was a small study (n = 38) and its findings were confounded by the combinational use of B-12 injection and oral folic acid.  These preliminary findings need to be validated by well-designed studies.

UpToDate reviews on “Initial treatment of fibromyalgia in adults” (Goldenberg, 2015a), “Treatment of fibromyalgia in adults not responsive to initial therapies” (Goldenberg, 2015b), “Fibromyalgia in children and adolescents: Treatment and prognosis” (Kimura and Walco, 2015) do not mention vitamin B-12 injection as a therapeutic option.

Furthermore, an UpToDate review on “Treatment of chronic fatigue syndrome (systemic exertion intolerance disease)” (Gluckman, 2015) states that “A number of medications and special diets have been evaluated in patients with CFS/SEID, but none has proved successful.  Among the modalities that have been tried are immune serum globulin, rituximab, acyclovir, galantamine, fluoxetine and other antidepressants, methylphenidate and modafinil (stimulants), glucocorticoids, amantadine, doxycycline, magnesium, evening primrose oil, vitamin B12, Ampligen, essential fatty acids, bovine or porcine liver extract, dialyzable leukocyte extract, cimetidine, ranitidine, interferons, exclusion diets, BioBran MGN-3 (a natural killer cell stimulant), and removal of dental fillings.  Only a few of these approaches have been tested in controlled trials.  A major problem with evaluating the effect of therapy in CFS/SEID is that the symptoms fluctuate over time, may remit spontaneously, and are subject to substantial response rates to placebo”.

Prevention of Osteoporotic Fracture

Ruan and colleagues (2015) stated that B vitamins (including folate, B-6, and B-12) supplementation can modify high plasma Hcy. However, the role of Hcy in the pathogenesis of osteoporotic fracture and bone turnover is still controversial.  In a meta-analysis, these investigators evaluated the impact of B vitamin supplementation on occurrence of any osteoporotic fracture and bone turnover by pooling the results of previous studies.  Relevant RCTs were searched in databases; data integration and analysis were done by using Review Manager 5.3 (the Cochrane Collaboration).  The RR and corresponding 95 % CI of fracture (intervention versus control) were estimated.  Changes in bone turnover indicators (continuous data), weighted mean difference (WMD), and corresponding 95 % CI were pooled for estimation.  Based on the results of 4 RCTs, this meta-analysis failed to identify a risk-reducing effect of daily supplementation of B vitamins on osteoporotic fracture in patients with vascular disease and with relatively normal plasma Hcy.  In addition, these researchers also did not find any positive effects of B vitamin supplementation on bone turnover.  The authors concluded that B vitamin supplementation might not be effective in preventing fracture and improving bone turnover.  However, the possible benefits in selective populations, such as populations with very high plasma Hcy and from regions without B vitamin fortification should be explored in the future.

Treatment of Delayed Sleep-Wake Phase Disorder and Non-24-Hour Sleep-Wake Rhythm Disorder

American Academy of Sleep Medicine’s updated clinical practice guideline on “Treatment of intrinsic circadian rhythm sleep-wake disorders” (Auger et al, 2015) provided the following recommendations:

• There is insufficient evidence to support the use of oral vitamin B12 (and no evidence to support alternate somatic interventions) among patients with delayed sleep-wake phase disorder (DSWPD) (versus no treatment). No recommendation.
• There is insufficient evidence to support the use of oral vitamin B12 (and no evidence to support alternate somatic interventions) among patients with non-24-hour sleep-wake rhythm disorder (N24SWD) (versus no treatment). No recommendation.

Treatment of Depression

In a systematic review, Almeida and associates (2015) examined if, compared with placebo, treatment with folate and/or vitamin B-12 reduces depression scale scores, increases remission, and prevents the onset of clinically significant symptoms of depression in people at risk. These investigators searched the PubMed, PsychInfo, Embase, and Cochrane databases from inception to June 6, 2014, using the following terms and strategy: (vitamin B12 or vitamin B9 or folate or folic acid or cobalamin or cyanocobalamin) and (depression or depressive disorder or depressive symptoms) and (randomized controlled trial or RCT).  The electronic search was supplemented by manual search.  Two independent reviewers assessed all papers retrieved for eligibility and bias, and extracted crude data.  Review Manager 5 was used to manage and analyze the data.  A total of 269 manuscripts were identified, of which 52 were RCTs and 11 fulfilled criteria for review.  These researchers found that the short-term use of vitamins (days to a few weeks) did not contribute to improve depressive symptoms in adults with major depression treated with anti-depressants (5 studies, standardized mean difference = -0.12, 95 % CI: -0.45 to 0.22), but more prolonged consumption (several weeks to years) may decrease the risk of relapse (1 study, OR = 0.33, 95 % CI: 0.12 to 0.94) and the onset of clinically significant symptoms in people at risk (2 studies, RR = 0.65, 95 % CI: 0.43 to 0.98).  The authors concluded that the number of available trials remained small and heterogeneity between studies high.  They stated that the results of these meta-analyses suggested that treatment with folate and vitamin B-12 did not decrease the severity of depressive symptoms over a short period of time, but may be helpful in the long-term management of special populations.

Age-Related Cataract

In a randomized, double-masked, placebo-controlled trial,, Christen and colleagues (2016) examined the incidence of cataract and cataract extraction in a trial of folic acid and vitamins B-6 and B-12.  A total of 5,442 female health professionals aged 40 years or older with pre-existing cardio-vascular disease (CVD) or 3 or more CVD risk factors were randomly assigned to receive a combination of folic acid (2.5 mg/day), vitamin B-6 (50 mg/day), and vitamin B-12 (1 mg/day), or placebo.  A total of 3,925 of these women did not have a diagnosis of cataract at baseline and were included in this analysis.  The primary end-point was age-related cataract, defined as an incident age-related lens opacity, responsible for a reduction in best-corrected visual acuity (BCVA) to 20/30 or worse, based on self-report confirmed by medical record review.  Extraction of incident age-related cataract was a secondary end-point of the trial.  During an average of 7.3 years of treatment and follow-up, 408 cataracts and 275 cataract extractions were documented.  There were 215 cataracts in the combination treatment group and 193 in the placebo group (hazard ratio [HR] 1.10, 95 % CI: 0.90 to 1.33; p = 0.36).  For the secondary end-point of cataract extraction, there were 155 in the combination treatment group and 120 in the placebo group (HR 1.28, 95 % CI: 1.01 to 1.63; p = 0.04).  The authors concluded that in this large-scale randomized trial of women at high risk of CVD, daily supplementation with a combination of folic acid, vitamin B-6, and vitamin B-12 had no significant effect on cataract, but may have increased the risk of cataract extraction.

Prevention of Cognitive Decline in Diabetic Individuals with Borderline Low Serum Vitamin B-12

Kwok and colleagues (2017) noted that older diabetic people are at risk of cognitive decline.  Vitamin B-12 deficiency in older people is associated with cognitive impairment and Alzheimer's disease.  Vitamin B-12 deficiency may therefore contribute to cognitive decline in older diabetic people.  These researchers performed a randomized placebo-controlled trial of vitamin B-12 supplementation to prevent cognitive decline in older diabetic people with mild vitamin B-12 deficiency.  A total of 271 diabetic non-demented out-patients aged 70 years or older with plasma vitamin B-12  of 150 to 300 pmol/L in out-patient clinics were randomly assigned to take either methylcobalamin 1,000 μg or 2 similar looking placebo tablets once-daily for 27 months.  All subjects were followed-up at 9 monthly intervals.  The primary end-point was cognitive decline as defined by an increase in clinical dementia rating scale (CDR) global score.  The secondary outcomes included Neuropsychological Test Battery (NTB) z-scores, serum MMA and Hcy.  The subjects in the trial groups were well-matched in clinical characteristics, except that active intervention group had more smokers; 46.5 % and 74.1 % had elevated serum MMA (greater than or equal to 0.21 μmol/L) and Hcy (greater than or equal to 13 μmol/L) respectively; 44 % of the subjects had CDR score of 0.5 suggesting questionable dementia.  At month 9 and 27, serum MMA and Hcy was significantly reduced in the active treatment group, when compared with placebo group (p < 0.0001, student t-test).  At month 27, there was no significant group difference in changes in CDR or NTB z-scores.  Exclusion of smokers did not alter the results; subgroup analysis of high MMSE and serum MMA showed similar results.  The authors concluded that vitamin B-12 supplementation did not prevent cognitive decline in older diabetic patients with borderline vitamin B-12 status.

Diabetic Peripheral Neuropathy

Jayabalan and Low (2016) stated that vitamin B-12 deficiency has been associated with significant neurological pathology, especially peripheral neuropathy.  These investigators examined the existing evidence on the effectiveness of vitamin B-12 supplementation for the treatment of diabetic peripheral neuropathy (DPN).  They performed a search of PubMed and the Cochrane Central Register of Controlled Trials for all relevant RCTs in December 2014.  Any type of therapy using vitamin B-12 or its co-enzyme forms was evaluated for safety and effectiveness in patients with DPN.  Changes in vibration perception thresholds, neuropathic symptoms and nerve conduction velocities, as well as the adverse effects of vitamin B-12 therapy, were assessed.  A total of 4 studies comprising 363 patients met the inclusion criteria.  The authors concluded that this review found no evidence that the use of oral vitamin B-12 supplements is associated with improvement in the clinical symptoms of DPN.  Furthermore, the majority of studies reported no improvement in the electrophysiological markers of nerve conduction.

Furthermore, and UpToDate review on “Treatment of diabetic neuropathy” (Feldman and McCulloch, 2017) does not mention vitamin B supplementation as a therapeutic option.

Peripheral Entrapment Neuropathies

Negrao and Nunes (2016) noted that carpal tunnel syndrome is the most common type of peripheral entrapment neuropathy.  On behalf of the Portuguese Group for the Study of Peripheral Neuropathy, these researchers performed an exploratory, open-label, multi-center, observational study of 48 patients with peripheral entrapment neuropathy.  Patients received a daily capsule of uridine monophosphate, folic acid + vitamin B-12 for 2 months and were evaluated using the Pain DETECT questionnaire.  The global score for pain decreased from 17.3 ± 5.9 at baseline to 10.3 ± 6.1 at the final evaluation (p < 0.001).  Concomitant analgesic and anti-inflammatory treatment was stopped or the dose reduced in 77.4 % of patients.  The authors concluded that uridine monophosphate + folic acid + vitamin B-12 reduced total pain score, intensity and characterization of pain and associated symptoms.  They stated that these findings should be tested in a well-designed, adequately powered RCT.

Tinnitus

In a randomized, double-blind, pilot study, Singh and colleagues (2016) examined the role of vitamin B-12 in treatment of chronic tinnitus.  A total 40 patients were enrolled, of which 20 in Group A (cases) received intra-muscular (IM) therapy of 1 ml vitamin B-12 (2,500 mcg) weekly for a period of 6 weeks, and Group B (n = 20) patients received placebo IM isotonic saline (1 m).  The patients were subjected to vitamin B-12 assay and audiometry pre- and post-therapy.  Of the total patients of tinnitus, 17 were vitamin B-12 deficient that is 42.5 % showed deficiency when the normal levels were considered to be 250 pg/ml.  A paired t-test showed that in Group A, patients with vitamin B-12 deficiency showed significant improvement in mean tinnitus severity index score and visual analog scale (VAS) after vitamin B-12 therapy.  The authors concluded that the findings of this pilot study shed light on the relationship of deficient B-12 levels and tinnitus and its supplementation playing a therapeutic role in tinnitus; though more studies with larger groups are needed to corroborate and establish a direct relationship.

Post-Herpetic Neuralgia

Wang and colleagues (2018) stated that post-herpetic neuralgia (PHN) is the most distressful complication of herpes zoster; PHN results in an impaired quality of life (QOL) and higher healthcare utilization.  These researchers carried out a systematic review and a meta-analysis to examine the efficacy of vitamin B12 supplementation in PHN patients.  PubMed, Embase, Cochrane Library, CINAHL, and ClinicalTrials.gov registry were searched; RCTs evaluating the safety and efficacy of vitamin B12 in PHN patients were selected.  Eligible trials were abstracted and assessed for the risk of bias by 2 reviewers, and the results of pain indicators in the selected trials were analyzed.  A total of 4 trials including 383 subjects were published between 2013 and 2016.  Compared with the placebo group, the vitamin B12 group exhibited a significant decrease in the Numeric Rating Scale (NRS) score, with a MD of -4.01 (95 % CI: -4.70 to -3.33).  Vitamin B12 administration improved the QOL of PHN patients with moderate quality evidence and significantly decreased the number of patients using analgesics.  The authors concluded that vitamin B12 appeared to be an attractive complementary therapy for PHN patients.  Moreover, these researchers stated that further investigation is needed before conclusive recommendations could be made.

Furthermore, an UpToDate review on “Postherpetic neuralgia” (Bajwa and Ortega, 2019) does not mention vitamin B-12 injection as a therapeutic option.

Amyotrophic Lateral Sclerosis

In a phase-II/III RCT, Kaji and colleagues (2019) examined the safety and efficacy of IM ultrahigh-dose of methylcobalamin (a form of vitamin B-12) in patients with amyotrophic lateral sclerosis (ALS).  A total of 373 patients with ALS (El Escorial definite or probable; laboratory-supported probable; duration  of less than or equal to 36 months) were randomly assigned to placebo, 25-mg or 50-mg of methylcobalamin groups.  The primary end-points were the time interval to primary events (death or full ventilation support) and changes in the Revised ALS Functional Rating Scale (ALSFRS-R) score from baseline to week 182.  Efficacy was also evaluated using post-hoc analyses in patients diagnosed early (entered less than or equal to 12 months after symptom onset).  No significant differences were detected in either primary end-point (minimal p = 0.087).  However, post-hoc analyses of methylcobalamin-treated patients diagnosed and entered early (less than or equal to 12 months' duration) showed longer time intervals to the primary event (p < 0.025) and less decreases in the ALSFRS-R score (p < 0.025) than the placebo group.  The incidence of treatment-related adverse events (AEs) was similar and low in all groups.  The authors concluded that although ultra-high-dose methylcobalamin did not demonstrate significant efficacy in the whole cohort, this treatment may prolong survival and retard symptomatic progression without major side effects if started early.

The authors stated that this study had several drawbacks.  First, the strict criteria for study inclusion may have excluded some patients with ALS, which has heterogeneous pathogeneses. Second, although post-hoc analysis identified only 1 subgroup of patients, additional factors may influence the safety and efficacy profile of methylcobalamin.  Third, these researchers did not examine higher doses (greater than 50 mg) for dose finding, and it is possible that these mega-doses might have even better outcome.  These researchers stated that these potential factors may warrant future analyses in other study cohorts such as the Japanese Early-stage Trial of High Dose Methylcobalamin for ALS (JETALS).

Furthermore, UpToDate reviews on “Symptom-based management of amyotrophic lateral sclerosis” (Galvez-Jimenez, 2020) and “Disease-modifying treatment of amyotrophic lateral sclerosis” (Galvez-Jimenez et al, 2020) and do not mention vitamin B-12 injection as a management / therapeutic option.

Appendix

Several commercial laboratories use different methods (chemiluminescence or radioassay) for measuring vitamin B12 (Schrier, 2011).  As a result, there are different normal ranges and no "gold standard".  In general, however, serum vitamin B12 levels can be interpreted, as follows:

• > 300 pg/ml (> 241 pmol/L): Normal result; vitamin B12 deficiency is unlikely (i.e., probability of 1 to 5 %).
• 200 to 300 pg/ml (148 to 241 pmol/L): Borderline result; vitamin B12 deficiency possible.
• < 200 pg/ml (< 148 pmol/L): Low; consistent with vitamin B12 deficiency (specificity of 95 to 100 %).

Note: The prescribing information of cyanocobalamin (vitamin B12) states that the drug is for intramuscular (IM) or subcutaneous (SC) use only.  The prescribing information also notes that administration of the drug via the intravenous (IV) route should be avoided since IV use of cyanocobalamin will result in almost all of the vitamin being lost in the urine. 

Table: CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Code Description
Information in the [brackets] below has been added for clarification purposes.   Codes requiring a 7th character are represented by "+":
CPT codes covered if selection criteria are met:
83090	Homocysteine
Other CPT codes related to the CPB:
96372	Therapeutic, prophylactic or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
HCPCS codes covered if selection criteria are met:
J3420	Injection, vitamin B-12 cyanocobalamin, up to 1000 mcg [covered for intramuscular or subcutaneous use only]
Other HCPCS codes related to the CPB:
J8610	Methotrexate, oral, 2.5 mg
J9250	Methotrexate sodium, 5 mg
J9260	Methotrexate sodium, 50 mg
J9305	Injection, pemetrexed, 10 mg
ICD-10 codes covered if selection criteria are met:
B70.0	Diphyllobothriasis
C16.0 - C16.9	Malignant neoplasm of stomach
C33 - C34.92	Malignant neoplasm of trachea, bronchus and lung [non squamous cell non-small cell lung cancer receiving pemetrexed (Alimta)]
C37	Malignant neoplasm of thymus [thymic carcinoma receiving pemetrexed (Alimta)]
C38.4	Malignant neoplasm of pleura [receiving pemetrexed (Alimta)]
C45.0	Mesothelioma of pleura [receiving pemetrexed (Alimta)]
C45.1	Mesothelioma of peritoneum [receiving pemetrexed (Alimta)]
C45.7	Mesothelioma of other sites [trachea, bronchus, lung] [receiving pemetrexed (Alimta)]
C48.2	Malignant neoplasm of peritoneum, unspecified [primary peritoneal cancer receiving pemetrexed (Alimta)]
C52	Malignant neoplasm of vagina [receiving pemetrexed (Alimta)]
C53.0 - C53.9	Malignant neoplasm of corpus uteri [receiving pemetrexed (Alimta)]
C56.1 - C57.02	Malignant neoplasm of ovary or fallopian tube [persistent or recurrent] [epithelial ovarian cancer] [receiving pemetrexed (Alimta)]
C61	Malignant neoplasm of prostate [urothelial carcinoma receiving pemetrexed (Alimta)]
C65.1 - C65.9	Malignant neoplasm of renal pelvis [receiving pemetrexed (Alimta)]
C66.1 - C66.9	Malignant neoplasm of renal pelvis [receiving pemetrexed (Alimta)]
C67.0 - C67.9	Malignant neoplasm of bladder [receiving pemetrexed (Alimta)]
C68.0	Malignant neoplasm of urethra [receiving pemetrexed (Alimta)]
C78.2	Secondary malignant neoplasm of pleura [mesothelioma] [non-small-cell lung cancer (NSCLC) receiving pemetrexed (Alimta)]
C82.50 - C82.59	Diffuse follicle center lymphoma [receiving methotrexate or pralatrexate (Folotyn)]
C83.30 - C83.39	Diffuse large B-cell lymphoma [primary CNS lymphoma receiving pemetrexed (Alimta)]
C84.00 - C84.09	Mycosis fungoides [receiving methotrexate or pralatrexate (Folotyn)]
C84.10 - C84.19	Sezary disease [receiving methotrexate or pralatrexate (Folotyn)]
C84.40 - C84.49	Peripheral T cell lymphoma, not classified [receiving methotrexate or pralatrexate (Folotyn)]
C84.60 - C84.79	Anaplastic large cell lymphoma [receiving methotrexate or pralatrexate (Folotyn)]
C84.A0 - C86.6	Cutaneous T-cell lymphoma unspecified, other mature T/NK-cell lymphomas, mature T/NK-cell lymphomas, other specified and unspecified types of non-Hodgkin lymphoma and other specified types of T/NK-cell lymphoma [relapsed or refractory monomorphic epitheliotropic receiving methotrexate or pralatrexate (Folotyn)]
C91.50 - C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated) [receiving methotrexate or pralatrexate (Folotyn)]
C91.Z0 - C91.Z2	Other lymphoid leukemia [adult T-cell lymphoma receiving methotrexate or pralatrexate (Folotyn)]
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency [Pernicious anemia, Addisonian, Biermer]
D51.1 - D51.9	Other Vitamin B12 deficiency anemias
D52.0	Dietary folate deficiency anemia
D53.1	Other megaloblastic anemias, not elsewhere classified
D53.9	Nutritional anemia, unspecified
E53.8	Deficiency of other specified B group vitamins
E71.120	Methylmalonic acidemia
E72.11	Homocystinuria
E72.50 - E72.9	Disorders of glycine metabolism [glycinemia with methyl-malonic acidemia]
G37.0 - G37.9	Other demyelinating diseases of central nervous system
G62.1	Alcoholic polyneuropathy
G90.01 - G90.9	Disorders of autonomic nervous system
G99.0	Autonomic neuropathy in diseases classified elsewhere [associated with pernicious anemia, malnutrition, alcoholism]
H46.10 - H46.13	Retrobulbar neuritis (acute)
H46.3	Toxic optic neuropathy [associated with heavy smoking, also known as tobacco amblyopia]
K31.1	Adult hypertrophic pyloric stenosis
K31.5	Obstruction of duodenum
K50.00 - K50.019	Regional enteritis of small intestine
K56.600-K56.609	Unspecified intestinal obstruction
K63.2	Fistula of intestine
K63.89	Other specified diseases of intestine
K90.0 - K90.9	Intestinal malabsorption
K91.1	Postgastric surgery syndromes
K91.2	Postsurgical malabsorption, not elsewhere classified
Z98.0	Intestinal bypass and anastamosis status
ICD-10 codes not covered for indications listed in the CPB (not all-inclusive):
B02.29	Other postherpetic nervous system involvement [post-herpetic neuralgia]
E08.40 - E08.49	Diabetes mellitus due to underlying condition with neurological complications [diabetic peripheral neuropathy]
E09.40 - E09.49	Drug or chemical induced diabetes mellitus with neurological complications [diabetic peripheral neuropathy]
E10.40 - E10.49	Type 1 diabetes mellitus with neurological complications [diabetic peripheral neuropathy]
E11.40 - E11.49	Type 2 diabetes mellitus with neurological complications [diabetic peripheral neuropathy]
E13.40 - E13.49	Other specified diabetes mellitus with neurological complications [diabetic peripheral neuropathy]
E66.0 - E66.9	Overweight and obesity
F32.0 - F33.9	Major depressive disorder
F84.0	Autistic disorder
G12.21	Amyotrophic lateral sclerosis
G13.2	Systemic atrophy primarily affecting the central nervous system in myxedema
G13.8	Systemic atrophy primarily affecting the central nervous system in other diseases classified elsewhere
G30.0 - G30.9	Alzheimer's disease
G31.01 - G31.09	Frontotemporal dementia
G31.1	Senile degeneration of brain, not elsewhere classified
G31.2	Degeneration of nervous system due to alcohol
G31.83	Dementia with Lewy bodies
G31.84	Mild cognitive impairment, so stated
G47.21	Circadian rhythm sleep disorder, delayed sleep phase type
G47.23	Circadian rhythm sleep disorder, irregular sleep wake type
G56.00 - G56.03	Carpal tunnel syndrome
G57.10 - G57.13	Meralgia paresthetica. Lateral cutaneous nerve of thigh syndrome
G57.50 - G57.53	Tarsal tunnel syndrome
G57.60 - G57.63	Lesion of plantar nerve [Morton's metatarsalgia]
G91.4	Hydrocephalus in diseases classified elsewhere
G94	Other disorders of brain in diseases classified elsewhere
H25.011 - H25.9	Age-related cataract
H93.11 - H93.19	Tinnitus
I60.00 - I69.998	Cerebrovascular diseases
M79.7	Fibromyalgia
M81.0 - M81.8	Osteoporosis without current pathological fracture
R53.82	Chronic fatigue syndrome
Z68.25 - Z68.45	Body Mass Index 25.0 - 70 or greater, adult [overweight and obesity]
Z68.54	Body mass index (BMI) pediatric, greater than or equal to 95th percentile for age [indicates BMI of 30 or above]
Z82.3	Family history of stroke

The above policy is based on the following references: